<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1964">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361643</url>
  </required_header>
  <id_info>
    <org_study_id>COVID19-EC01</org_study_id>
    <nct_id>NCT04361643</nct_id>
  </id_info>
  <brief_title>Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial</brief_title>
  <acronym>GETAFE</acronym>
  <official_title>Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Getafe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Getafe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind randomized controlled clinical trial (RCT) of low-dose lenalidomide in the&#xD;
      treatment of elderly patients (&gt; 60 years of age) with mild to moderate clinical signs of&#xD;
      COVID-19 disease from the Hospital Universitario of Getafe.&#xD;
&#xD;
      The study will include patients of both sexes (&gt; 60 years of age) with mild to moderate&#xD;
      clinical presentation of COVID-19 (ROX index &gt; 10). Subjects will be randomly assigned to the&#xD;
      experimental arm with lenalidomide (5 mg/24h, day 1, 3 and 5) or to the controlled arm. Other&#xD;
      concomitant medication for the treatment of COVID-19 will be also considered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>30 days</time_frame>
    <description>Days to clinical recovery or days until discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune-inflammatory improvement</measure>
    <time_frame>30 days</time_frame>
    <description>o Improvement of the neutrophil-to-lymphocyte ratio (NLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality at 30 days after enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a placebo capsule PO daily, days 1, 3, and 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.</intervention_name>
    <description>Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects &gt; 60 years of age&#xD;
&#xD;
          -  Diagnosed case (PCR test for COVID-19 if available) or COVID-19 clinical symptoms&#xD;
             (defined as fever, dry cough, dyspnea, chest radiography with compatible findings with&#xD;
             COVID-19)&#xD;
&#xD;
          -  Lymphocyte count ≥ 0.2 x 103/µL and ≤1.0 x 103/µL.&#xD;
&#xD;
          -  Neutrophil count ≥ 1.8 x 103/µL, platelets ≥ 150 x 103/µL.&#xD;
&#xD;
          -  ROX ≥ 10 index&#xD;
&#xD;
          -  Signed informed consent document&#xD;
&#xD;
          -  Willing to comply with the lenalidomide Risk Minimization Program (Pregnancy&#xD;
             Prevention Program approved)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute contraindication of lenalidomide use or hypersensitivity to the active&#xD;
             ingredient or any of the excipients.&#xD;
&#xD;
          -  Active neoplasia&#xD;
&#xD;
          -  Previous autoimmune disease&#xD;
&#xD;
          -  Concurrent infection of HBV, HCV or tuberculosis.&#xD;
&#xD;
          -  Aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 3 times the upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          -  Bilirubin levels &gt; 1.5 times the ULN&#xD;
&#xD;
          -  Renal impairment with an estimated GF &lt; 30ml/min&#xD;
&#xD;
          -  Venous thromboembolism events within the previous 3 years&#xD;
&#xD;
          -  Significant active heart disease within the previous 6 months, including congestive&#xD;
             heart failure (class II-IV NYHA), unstable angina or myocardial infarctions&#xD;
&#xD;
          -  Sexually active subjects who refuse the lenalidomide Risk Minimization Program&#xD;
&#xD;
          -  Inability to comply with the working protocol under the responsible health&#xD;
             professional opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquin De Haro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Getafe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joaquin De Haro, MD</last_name>
    <phone>+34 626022977</phone>
    <email>deharojoaquin@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Joaquin De Haro, MD,PhD</last_name>
      <phone>+34 916 839 360</phone>
      <email>deharojoaquin@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Joaquin De Haro, MD, PhD</last_name>
      <phone>+34 916 839 360</phone>
      <email>deharojoaquin@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Joaquin De Haro, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

